Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

RecruitingOBSERVATIONAL

Enrollment

690

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

April 13, 2026

Study Completion Date

April 13, 2026

Conditions

Hepatitis BHaemophilus Influenzae Type b Immunisation

Interventions

BIOLOGICAL

DTaP-IPV-Hep B-PRP-T combined vaccine

prefilled syringe injection intramuscular

Trial Locations (2)

RECRUITING

Investigational Site Number : 002, Cheonan

RECRUITING

Investigational Site Number : 001, Seoul

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY